Trial · NCT07469722
POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
NCT07469722, Phase 2, Phase 3, Not yet recruiting, Hospital de Clinicas de Porto Alegre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure. Trials, record NCT07469722. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07469722
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
- NCT number
- NCT07469722
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Hospital de Clinicas de Porto Alegre
- Conditions
- Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect, Lung Ultrasonography Score, Ultrasonography, Doppler, Point-of-care Ultrasound (POCUS)
- Interventions
- Furosemide 40 Milligrams., Furosemide 40 Milligrams., Hydrochlorothiazide (HCTZ) 25 milligrams., Acetazolamide 250 milligrams., Dapagliflozin (10mg Tab), Potassium Chloride Oral Product
- First posted
- 2026-03-13
- Last updated
- 2026-03-18
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pairwise Comparisons With Wins of Clinical Benefit, a Composite of In-Hospital Mortality, Hospital Length of Stay, Absence of Congestion on DUCS at Discharge, and BNP Reduction From Admission to Day 7 or Discharge. | From randomization until hospital discharge (assessed up to 90 days). | Clinical benefit will be assessed using a hierarchical composite endpoint based on pairwise comparisons (win ratio analysis), including the following components, analyzed in a predefined hierarchical order: 1. In-hospital mortality: death is worse than no death; earlier death is worse than later death; tied if not possible to determine. 2. Hospital length of stay (days): a shorter hospital length of stay is better; a difference of ≥1 day defines a win; tied if the same number of length of stay days. 3. Absence of congestion on DUCS at discharge: \<2 points at discharge on DUCS is better; tied if both have ≥2 points or if both have \<2 points on DUCS. 4. BNP reduction at day 7 or discharge (whichever occurs first): a reduction of ≥30% in BNP is better; tied if both achieve or do not achieve a ≥30% reduction. |
| Secondary | All-cause in-hospital mortality. | From randomization until hospital discharge (assessed up to 90 days). | All-cause mortality occurring between hospital admission and discharge will be analyzed to compare the treatment groups. |
| Secondary | Hospital length of stay. | From randomization until hospital discharge (assessed up to 90 days). | Hospital length of stay, measured in days, will be compared between treatment groups. |
| Secondary | Proportion of patients without congestion on POCUS at discharge. | From randomization until hospital discharge (assessed up to 90 days). | Absence of residual congestion at hospital discharge, defined as DUCS \<2 points, will be compared between the intervention group and the standard-of-care group. |
| Secondary | BNP reduction. | From randomization until hospital discharge (assessed up to 90 days). | The proportion of patients achieving a ≥30% reduction in BNP from hospital admission to day 7 or hospital discharge (whichever occurs first) will be compared between the intervention and control groups. |
| Secondary | Change in body weight. | From randomization until hospital discharge (assessed up to 90 days). | Change in body weight, measured in kilograms, between hospital admission and discharge will be compared between treatment groups. |
| Secondary | Change in dyspnea assessed by the Visual Analogue Scale (VAS). | Up to day 5. | The area under the curve (AUC) of change in VAS dyspnea score will be compared between treatment groups. Individual scores will be plotted over time, with the x-axis representing study days from baseline to day 5, and the y-axis representing the VAS score (0-100 millimeters). The VAS AUC (millimeter x hour) will be compared between treatment groups. |
| Secondary | Proportion of participants with worsening renal function. | Up to day 7. | Worsening renal function will be defined as an increase of ≥0.3 mg/dL in serum creatinine or a ≥50% increase from baseline within 7 days. |
| Secondary | Proportion of patients without congestion on EVEREST at discharge. | From randomization until hospital discharge (assessed up to 90 days). | The proportion of patients with EVEREST composite congestion score (CCS) ≤ 2 points at hospital discharge will be compared between treatment groups. |
| Secondary | In-hospital mortality and major in-hospital clinical events. | From randomization until hospital discharge (assessed up to 90 days). | A composite outcome including in-hospital mortality, admission to intensive care unit, use of mechanical ventilation, renal replacement therapy, vasopressor use, or inotrope use during the index hospitalization will be assessed and compared between treatment groups. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37448210 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07469722
GET https://conductscience.org/api/trials/v1/NCT07469722/registered